Related Experiment Video
Updated: Jun 2, 2026
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Advances in the treatment of small-cell lung cancer
1Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109-5848, USA. kalemker@umich.edu
Abstract:
Small-cell lung cancer (SCLC) is an aggressive malignancy characterized by early metastatic dissemination and responsiveness to initial therapy. The incidence of SCLC has been declining over the past decade, mainly due to a decreased incidence in men. Positron-emission tomographic (PET) scans appear to improve the accuracy of staging and treatment planning in patients with SCLC. Limited-stage (LS) SCLC is a potentially curable disease, with long-term survival of ~20% when treated with platinum-based chemotherapy plus concurrent thoracic radiation. Hyperfractionated thoracic radiation and prophylactic cranial irradiation (PCI) may significantly improve overall survival in selected patients with LS-SCLC. For patients with extensive-stage (ES) SCLC, survival can be increased with combination chemotherapy, but the disease remains incurable, and long-term survival is rare. The use of PCI has recently been reported to further improve overall survival in ES-SCLC. Several newer cytotoxic agents, such as amrubicin, have promising activity in early clinical trials. Although many potential molecular targets have been identified in preclinical studies of SCLC, molecularly targeted therapy has yet to demonstrate any substantial activity in clinical trials. Nonetheless, future advances in this disease will undoubtedly depend on improvements in our understanding of the molecular mechanisms that drive the proliferation and survival of SCLC cells.
Insights
Small-cell lung cancer (SCLC) survival rates are improving with advanced treatments like thoracic radiation and prophylactic cranial irradiation (PCI). Further research into molecular mechanisms is crucial for developing effective targeted therapies for this aggressive malignancy.
Area of Science:
- Oncology
- Pulmonology
Background:
- Small-cell lung cancer (SCLC) is an aggressive malignancy with early metastasis.
- SCLC incidence is declining, particularly in men.
- Positron-emission tomographic (PET) scans enhance staging and treatment planning for SCLC.
Purpose of the Study:
- To review current treatment strategies and survival outcomes for limited-stage (LS) and extensive-stage (ES) SCLC.
- To highlight the role of radiation therapy, including prophylactic cranial irradiation (PCI), in improving survival.
- To discuss emerging therapies and the future direction of SCLC research.
Main Methods:
- Review of current literature on SCLC treatment modalities.
- Analysis of survival data for LS-SCLC and ES-SCLC patients.
- Evaluation of the impact of chemotherapy, radiation, and PCI on patient outcomes.
Main Results:
- LS-SCLC offers potential for long-term survival (~20%) with platinum-based chemotherapy and thoracic radiation.
- Hyperfractionated radiation and PCI significantly improve survival in selected LS-SCLC patients.
- Combination chemotherapy increases survival in ES-SCLC, with PCI showing further benefit, though the disease remains largely incurable.
Conclusions:
- SCLC treatment has advanced, with radiation and PCI improving survival for both LS and ES disease.
- Newer cytotoxic agents show promise, but molecularly targeted therapies have yet to yield substantial clinical benefits.
- Future progress in SCLC hinges on a deeper understanding of its underlying molecular drivers.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...